Astellas Pharma has reported topline findings from the Phase III MOONLIGHT 3 clinical trial of fezolinetant to treat moderate to severe vasomotor symptoms (VMS) linked to menopause in women in mainland China. 

The single-arm trial analysed the long-term safety and tolerability of 30mg fezolinetant given once a day for 52 weeks for providing relief of menopause-linked VMS. 

It enrolled 150 women in mainland China.

The frequency and severity of adverse events (AEs) was the trial’s primary endpoint.

According to the findings, the AEs were found to be generally in line with those seen in prior Phase III trials of fezolinetant. 

An oral, nonhormonal compound, fezolinetant is an investigational selective neurokinin-3 (NK3) receptor antagonist. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

A New Drug Application for fezolinetant to treat moderate to severe VMS linked to menopause is currently being reviewed in the US. 

This submission is based on findings from the Phase III SKYLIGHT 1 and SKYLIGHT 2 trials, as well as the Phase III SKYLIGHT 4, a long-term safety trial.

Astellas Development Therapeutic Areas senior vice-president and head Ahsan Arozullah said: “The topline results from the MOONLIGHT 3 study are very encouraging and, upon initial review, further support the long-term safety of fezolinetant. 

“We are evaluating the full MOONLIGHT data sets and remain committed to developing innovative treatments in this therapeutic area, with the hope of delivering a first-in-class, nonhormonal treatment option for women with moderate to severe VMS.”

VMS are characterised by hot flashes and/or night sweats and are prevalent menopause symptoms.

In February last year, the company reported positive data from the Phase III SKYLIGHT 1 and SKYLIGHT 2 trials of fezolinetant  to treat moderate to severe menopause-associated VMS.